The U.S. Court of Appeals for the Fifth Circuit upheld the FDA’s decision to declare the semaglutide injection shortage over, clearing the way to curb large-scale compounding of Ozempic and Wegovy copies and reinforcing that compounded products are not interchangeable with FDA-approved drugs. For clinicians, the ruling could affect access pathways, prescribing conversations, and patient counseling on dosing, quality, and regulatory oversight.

The Move

• The Fifth Circuit affirmed a lower court ruling backing the FDA’s determination that shortages of Novo Nordisk’s semaglutide injections, Ozempic and Wegovy, had ended.

• Compounding groups argued the agency acted improperly in removing the drugs from the shortage list, but the court rejected claims that the FDA was arbitrary or capricious.

• The court also said any procedural error was harmless because compounders had notice, submitted extensive information, and did not show that a more formal process would have changed the outcome.

Why It Matters for Care

• Clinicians may see fewer legally available mass-compounded semaglutide products marketed as alternatives to branded injections.

• That matters at the bedside because compounded semaglutide products are not FDA-approved and have been linked by the agency to dosing errors and other risks.

• Expect more patient questions about whether compounded versions remain available, whether they are equivalent, and how to navigate dose-specific access if local pharmacy supply remains uneven.

Between the Lines

• The broader policy fight is over whether shortage exemptions are temporary emergency tools or a durable business model for compounders once demand persisted after supply improved.

• The opinion strengthens the FDA’s hand to define when a shortage ends using system-wide supply data, rather than anecdotal reports, social media complaints, or isolated local stockouts.

• It also protects the approval framework by signaling that commercial popularity or lower price does not extend a statutory exception for copying an approved drug.

What to Watch

• FDA enforcement: Watch for agency action against firms that continue routine semaglutide copying under the banner of personalization or patient-specific compounding.

• Supply monitoring: Manufacturers will face pressure to keep providing current, verifiable production and distribution data to support the claim that the shortage is truly over.

• Practice impact: State regulators, telehealth platforms, and pharmacies may update policies on dispensing, advertising, and counseling around compounded GLP-1 products.

Source: RealClearHealth